Quest Diagnostics Price to Free Cash Flow Ratio 2010-2024 | DGX
Historical price to free cash flow ratio values for Quest Diagnostics (DGX) since 2010.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Quest Diagnostics Price to Free Cash Flow Ratio Historical Data |
| Date |
Stock Price |
TTM FCF per Share |
Price to FCF Ratio |
| 2024-09-26 |
154.42 |
|
19.82 |
| 2024-06-30 |
136.15 |
$7.79 |
17.47 |
| 2024-03-31 |
131.64 |
$8.38 |
15.70 |
| 2023-12-31 |
135.64 |
$7.65 |
17.74 |
| 2023-09-30 |
119.19 |
$5.17 |
23.04 |
| 2023-06-30 |
136.79 |
$7.58 |
18.03 |
| 2023-03-31 |
137.00 |
$7.40 |
18.52 |
| 2022-12-31 |
150.81 |
$11.14 |
13.54 |
| 2022-09-30 |
117.66 |
$11.90 |
9.88 |
| 2022-06-30 |
126.90 |
$12.50 |
10.15 |
| 2022-03-31 |
129.96 |
$12.97 |
10.02 |
| 2021-12-31 |
163.55 |
$14.30 |
11.44 |
| 2021-09-30 |
136.77 |
$14.80 |
9.24 |
| 2021-06-30 |
123.64 |
$16.50 |
7.50 |
| 2021-03-31 |
119.66 |
$15.23 |
7.86 |
| 2020-12-31 |
110.62 |
$11.67 |
9.48 |
| 2020-09-30 |
105.76 |
$10.15 |
10.42 |
| 2020-06-30 |
104.77 |
$6.00 |
17.46 |
| 2020-03-31 |
73.30 |
$5.74 |
12.78 |
| 2019-12-31 |
97.00 |
$6.20 |
15.65 |
| 2019-09-30 |
96.73 |
$5.90 |
16.38 |
| 2019-06-30 |
91.54 |
$6.76 |
13.55 |
| 2019-03-31 |
80.38 |
$6.78 |
11.85 |
| 2018-12-31 |
73.96 |
$5.88 |
12.58 |
| 2018-09-30 |
95.39 |
$6.56 |
14.53 |
| 2018-06-30 |
96.75 |
$6.39 |
15.14 |
| 2018-03-31 |
87.82 |
$6.27 |
14.01 |
| 2017-12-31 |
85.85 |
$6.59 |
13.02 |
| 2017-09-30 |
81.23 |
$6.44 |
12.61 |
| 2017-06-30 |
96.03 |
$6.00 |
16.01 |
| 2017-03-31 |
84.44 |
$6.15 |
13.73 |
| 2016-12-31 |
78.64 |
$5.80 |
13.57 |
| 2016-09-30 |
72.42 |
$5.45 |
13.28 |
| 2016-06-30 |
69.00 |
$4.87 |
14.18 |
| 2016-03-31 |
60.22 |
$4.61 |
13.06 |
| 2015-12-31 |
59.63 |
$3.85 |
15.49 |
| 2015-09-30 |
51.21 |
$4.14 |
12.38 |
| 2015-06-30 |
60.10 |
$4.20 |
14.31 |
| 2015-03-31 |
63.37 |
$4.25 |
14.92 |
| 2014-12-31 |
55.03 |
$4.39 |
12.55 |
| 2014-09-30 |
49.52 |
$3.72 |
13.31 |
| 2014-06-30 |
47.64 |
$3.48 |
13.68 |
| 2014-03-31 |
46.75 |
$2.87 |
16.26 |
| 2013-12-31 |
42.97 |
$2.75 |
15.62 |
| 2013-09-30 |
49.59 |
$3.92 |
12.64 |
| 2013-06-30 |
48.43 |
$5.16 |
9.38 |
| 2013-03-31 |
44.88 |
$5.45 |
8.24 |
| 2012-12-31 |
45.83 |
$6.28 |
7.30 |
| 2012-09-30 |
49.89 |
$6.08 |
8.21 |
| 2012-06-30 |
46.99 |
$5.79 |
8.11 |
| 2012-03-31 |
47.84 |
$4.66 |
10.27 |
| 2011-12-31 |
45.16 |
$4.59 |
9.84 |
| 2011-09-30 |
38.31 |
$4.23 |
9.06 |
| 2011-06-30 |
45.87 |
$4.05 |
11.34 |
| 2011-03-31 |
44.65 |
$4.81 |
9.29 |
| 2010-12-31 |
41.67 |
$5.15 |
8.10 |
| 2010-09-30 |
38.97 |
$5.33 |
7.31 |
| 2010-06-30 |
38.27 |
$5.41 |
7.08 |
| 2010-03-31 |
44.75 |
$4.29 |
10.42 |
| 2009-12-31 |
46.28 |
$4.42 |
10.46 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Outpatient & Home Care |
$17.232B |
$9.252B |
|
Quest Diagnostics, Inc. is the provider of commercial laboratory services. Quest provides lab testing services to physicians, hospitals, managed care organizations, employers, government institutions and other clinical laboratories. The company consists of 2 business groups - Diagnostic Information Services and Diagnostic Solutions. The company's focus is on two elements - to accelerate growth and to drive operational excellence. Restore Growth: The company has adopted seven tactical approaches to accelerate growth such as sales and marketing; development of esoteric testing through a disease focus; partnerships with hospitals and successful testing of international IDNs; creation of value from information assets; leadership in companion diagnostics; extension into adjacent markets. Drive Operational excellence: The company plans to focus on four strategic requirements - to enhance end-to-end customer value chain, enterprise information technology architecture, business performance tools and cost excellence.
|
